Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors (Q46703065)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors |
scientific article |
Statements
1 reference
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors (English)
1 reference
Jaap Verweij
1 reference
Ferry A L M Eskens
1 reference
Maja J A de Jonge
1 reference
Pankaj Bhargava
1 reference
Toshiyuki Isoe
1 reference
Monette M Cotreau
1 reference
Brooke Esteves
1 reference
Kunihiko Hayashi
1 reference
Herman Burger
1 reference
Maarten Thomeer
1 reference
Leni van Doorn
1 reference
5 October 2011
1 reference
1 reference
17
1 reference
22
1 reference
7156-7163
1 reference
Identifiers
1 reference
1 reference